PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
28-Oct-2024 Global Lupus Nephritis Treatment Market Set to Surpass USD 5.67 Billion by 2033 at a 11% CAGR, Driven by Innovative Therapies and Increased Disease Awareness MARKITWIRED
28-Oct-2024 England's Health Ombudsman comments on the CQC's State of Care report PHSO
28-Oct-2024 iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress iTeos Therapeutics, Inc
28-Oct-2024 NEW RESEARCH REVEALS LACK OF AWARENESS AROUND ELIGIBILITY FOR WINTER VACCINES Moderna
28-Oct-2024 Innovative back pressure regulator launched by Vapourtec Vapourtec
28-Oct-2024 Travel, work and medical anxiety: The main reasons why millions are missing hospital appointments, costing the NHS £960m a year DrDoctor
28-Oct-2024 ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital Increase with Cornerstone Investment from Ottobock SE & Co. KGaA ONWARD Medical N.V.
28-Oct-2024 PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes PolTREG
28-Oct-2024 New imaging technique could spot patients with aggressive brain tumours who would benefit from immunotherapy The Institute of Cancer Research
28-Oct-2024 enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R) AccessWire
28-Oct-2024 Duhn Therapeutics, launched by Landmark BioVentures, signs global license agreement with OM Pharma to further advance clinical-stage, lipid-based cancer immunotherapy Duhn Therapeutics
28-Oct-2024 CluePoints Appoints Richard Young as Chief Strategy Officer CluePoints
28-Oct-2024 CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting AccessWire
28-Oct-2024 CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting CureVac
28-Oct-2024 Tenon Medical(R) Regains Full Compliance with Nasdaq Continued Listing Requirements AccessWire
28-Oct-2024 Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets AccessWire
28-Oct-2024 MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain AccessWire
28-Oct-2024 MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain Newswire
28-Oct-2024 Nuclear Medicine Specialist Ken Herrmann Joins Supervisory Board of Pentixapharm Holding AG Pentixapharm Holding AG
28-Oct-2024 NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements AccessWire